In an adult female patient on bupropion (Wellbutrin) for depression and attention‑deficit symptoms who has been stable for several months but now presents with insomnia and increased irritability, what is the appropriate next management step?

Management of New-Onset Insomnia and Irritability in Patient on Bupropion

Reduce the bupropion dose or consider switching to a different antidepressant, as insomnia and irritability are recognized adverse effects of bupropion that may represent emerging treatment-related toxicity rather than disease progression.

Rationale Based on FDA Drug Label

The FDA label for Wellbutrin explicitly identifies insomnia and irritability as known adverse effects that warrant clinical attention 1. Critically, the label states: "The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants" 1.

The FDA label specifically recommends: "Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms" 1.

Clinical Decision Algorithm

Step 1: Assess Severity and Timing

• If symptoms are severe or abrupt: Discontinue bupropion immediately and consider alternative antidepressant
• If symptoms are moderate and gradual: Proceed to dose reduction strategy

Step 2: Dose Reduction Strategy

• Reduce current dose by 50% (e.g., from 300mg to 150mg daily)
• Monitor for 2-4 weeks for symptom resolution
• If insomnia/irritability resolve but depression/inattention worsen, proceed to Step 3

Step 3: Medication Switch

Consider switching to:

• SSRI/SNRI if anxiety component is prominent (SSRIs show modest advantage in highly anxious presentations) 2
• Stimulant medication for ADHD symptoms if depression is well-controlled
• Combination therapy with lower-dose bupropion plus SSRI if partial response to bupropion was good

Step 4: Address Insomnia Directly

If insomnia persists despite dose adjustment:

• First-line: Cognitive behavioral therapy for insomnia (CBT-I) per ACP guidelines 3
• Second-line pharmacotherapy (only if CBT-I unsuccessful): Consider short-term use of non-benzodiazepine hypnotics, ramelteon, or low-dose doxepin 4

Key Clinical Considerations

Bupropion's stimulating properties are mediated through dopamine and norepinephrine reuptake inhibition 5, 6. While this mechanism benefits depression and attention symptoms, it inherently carries risk for insomnia and agitation, particularly at higher doses 7.

Important distinction: Research shows that baseline insomnia does NOT predict poor response to bupropion 8, but emergent insomnia during treatment represents a different phenomenon—likely dose-related adverse effects rather than treatment failure.

Recent evidence suggests bupropion can worsen anxiety symptoms in some patients, particularly those with severe baseline anxiety 2, 7. The 2025 systematic review found SSRIs showed modest advantage over bupropion specifically in patients with high baseline anxiety 2.

Common Pitfalls to Avoid

1. Don't increase the dose: Insomnia and irritability are dose-related side effects that will worsen with dose escalation 1

2. Don't add sedating medications first: Address the root cause (bupropion's stimulating effects) before layering additional medications for symptom management

3. Don't assume depression is worsening: These symptoms may represent medication side effects rather than disease progression, especially given prior stability

4. Don't ignore the timeline: The FDA label emphasizes monitoring "especially during the initial few months of a course of drug therapy, or at times of dose changes" 1—this patient's symptoms emerging after months of stability suggests either dose accumulation effects or tolerance issues

Monitoring Plan

• Weekly assessment for first 2-4 weeks after any dose change
• Screen for: Worsening depression, suicidal ideation, hypomania/mania (bupropion can precipitate mood elevation) 1
• Document: Sleep quality, irritability severity, depression symptoms, and attention/concentration

The FDA explicitly states that families and caregivers should "monitor patients for the emergence of agitation, irritability, unusual changes in behavior" and "report such symptoms immediately to healthcare providers" 1. This patient's presentation fits this warning profile precisely.